| Date | Time | Source | Headline | Symbol | Company |
| 01/02/2024 | 1:00AM | GlobeNewswire Inc. | Galapagos signs agreement to transfer Jyseleca® business to Alfasigma | EU:GLPG | Galapagos |
| 12/19/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 | EU:GLPG | Galapagos |
| 12/19/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 | EU:GLPG | Galapagos |
| 12/09/2023 | 12:00PM | GlobeNewswire Inc. | Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 | EU:GLPG | Galapagos |
| 12/09/2023 | 12:00PM | GlobeNewswire Inc. | Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 | EU:GLPG | Galapagos |
| 12/07/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 | EU:GLPG | Galapagos |
| 12/07/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 | EU:GLPG | Galapagos |
| 11/02/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 | EU:GLPG | Galapagos |
| 11/02/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 | EU:GLPG | Galapagos |
| 10/30/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma | EU:GLPG | Galapagos |
| 10/30/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma | EU:GLPG | Galapagos |
| 09/19/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Simon Sturge to its Board of Directors | EU:GLPG | Galapagos |
| 09/19/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Simon Sturge to its Board of Directors | EU:GLPG | Galapagos |
| 08/28/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus | EU:GLPG | Galapagos |
| 08/28/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus | EU:GLPG | Galapagos |
| 08/03/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces first half-year 2023 financial results | EU:GLPG | Galapagos |
| 08/03/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces first half-year 2023 financial results | EU:GLPG | Galapagos |
| 06/15/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer | EU:GLPG | Galapagos |
| 06/15/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer | EU:GLPG | Galapagos |
| 06/12/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board | EU:GLPG | Galapagos |
| 06/12/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board | EU:GLPG | Galapagos |
| 06/05/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress | EU:GLPG | Galapagos |
| 06/05/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress | EU:GLPG | Galapagos |
| 05/23/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis | EU:GLPG | Galapagos |
| 05/23/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis | EU:GLPG | Galapagos |
| 05/22/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 | EU:GLPG | Galapagos |
| 05/22/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 | EU:GLPG | Galapagos |
| 05/05/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos creates new subscription right plans | EU:GLPG | Galapagos |
| 05/05/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos creates new subscription right plans | EU:GLPG | Galapagos |
| 05/04/2023 | 4:01PM | GlobeNewswire Inc. | Galapagos announces first quarter 2023 financial results | EU:GLPG | Galapagos |